Need for More Randomized Controlled Trials With Rigorous Methodology to Confirm That Ivermectin Is Not a Viable Option for the Treatment of Coronavirus Disease 2019
Clin Infect Dis
.
2022 Mar 23;74(6):1121-1122.
doi: 10.1093/cid/ciab689.
Authors
Masahiro Banno
1
2
3
,
Yasushi Tsujimoto
3
4
5
,
Masahiro Ishikane
6
Affiliations
1
Department of Psychiatry, Seichiryo Hospital, Showa-ku, Nagoya, Japan.
2
Department of Psychiatry, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
3
Systematic Review Workshop Peer Support Group, Osaka, Japan.
4
Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Sakyo-ku, Kyoto, Japan.
5
Department of Nephrology and Dialysis, Kyoritsu Hospital, Kawanishi, Japan.
6
Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
PMID:
34358296
PMCID:
PMC8385944
DOI:
10.1093/cid/ciab689
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
COVID-19 Drug Treatment*
Humans
Ivermectin* / therapeutic use
Randomized Controlled Trials as Topic
SARS-CoV-2
Substances
Ivermectin